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Abstract
Tumor growth and metastasis are determined by the complex interplay of factors, including those intrinsic to tumor cells
and extrinsic factors associated with the tumor microenvironment. Our previous work demonstrated key roles for CD34 in
the maintenance of vascular integrity and eosinophil and mast cell homing. Since both of these functions affect tumor
development, we characterized the effect of CD34 ablation on tumor growth using the B16F1 melanoma model.
Intriguingly, we found that CD34 plays a biphasic role in tumor progression. In early growth, both subcutaneous-injected
tumors and intravenous-injected lung metastases grew more slowly in Cd34
2/2 mice. This correlated with abnormal vessel
morphology and increased vascular permeability in these mice. Bone marrow transplantation experiments confirmed that
this reflects a non-hematopoietic function of CD34. At later stages, subcutaneous tumor growth was accelerated in Cd34
2/2
mice and surpassed growth in wildtype mice. Bone marrow chimera experiments demonstrated this difference was due to a
hematopoietic function for CD34 and, correspondingly we found reduced intra-tumor mast cell numbers in Cd34
2/2 mice.
In aggregate, our analysis reveals a novel role for CD34 in both early and late tumor growth and provides novel insights into
the role of the tumor microenvironment in tumor progression.
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Introduction
Cancer results from a complex series of pre-neoplastic genetic
lesions in cells that go on to form tumors. Once cells gain tumor-
forming potential, their expansion and spread is determined by
complex interactions between tumor cells and the surrounding
microenvironment. Early growth is governed by proliferation and
death of tumor cells and cues from the local microenvironment,
resulting in angiogenesis and integration into the local vasculature
[1–3]. Subsequent growth is affected by tissue remodeling, the
supply of pro-tumorigenic factors and evasion of anti-tumor
immune responses. Extensive study has focused on initial mutations
in carcinogenesis and led to seminal insights into the roles of
oncogenes in tumor progression. While these studies provide insight
into tumor initiation, a growing body of literature recognizes the
importance of the surrounding microenvironment on tumor
growth. In this study, we focused on the function of the membrane
protein CD34 in the tumor-extrinsic microenvironment.
CD34 is a cell surface sialomucin best known for its expression
on hematopoietic stem cell/progenitor cells, and also expressed by
vascular endothelia [4], eosinophils [5–7] and mast cells [8].
Although CD34 is frequently used to identify progenitor cells,
surprisingly little is known about its function. One exception is its
role as an L-selectin ligand on the high endothelial venules (HEV),
where a specific sialyl Lewis-X modification allows L-selectin
binding [9]. However, this modification is limited to the HEV and
CD34 function on the vast majority of vasculature and other cell
types remains cryptic.
On endothelial cells, CD34 and the related molecule podoca-
lyxin play an important role in vessel development and function
[10,11]. During embryonic vascular development, CD34 and
podocalyxin colocalize to sites of lumen formation in the
embryonic aorta and adult tumor-associated vessels [10]. Strik-
ingly, Podxl
2/2 embryos exhibited delayed lumen formation,
suggesting that podocalyxin is required for proper vessel formation
[10]. A role for endothelial CD34 in maintaining vascular integrity
was also proposed in two independent inflammatory models
(autoimmune arthritis and TNFa inflamed muscle), as Cd34
2/2
mice exhibited increased vascular leakage and edema compared to
Cd34
+/+ controls [11]. These studies suggest an important role for
CD34 and related molecules in vasculogenesis and vessel
maintenance.
On hematopoietic cells, we demonstrated a role for CD34 in
facilitating mast cell and eosinophil migration. Mast cells derived
from Cd34
2/2 bone marrow exhibited increased homotypic
adhesion and impaired trafficking in vivo, compared to Cd34
+/+
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2/2 animals also exhibited reduced tissue
eosinophil recruitment in asthma and ulcerative colitis models and
Cd34
2/2 eosinophils demonstrated a cell-intrinsic reduction in
chemotaxis in vitro [6,7].
A variety of hematopoietic cells, including eosinophils and mast
cells, which both express CD34, infiltrate tumor sites and interact
with tumor cells and the surrounding microenvironment [13,14].
Local mast cells modulate tumor angiogenesis, tissue remodeling
and the host immune response against developing tumors [14].
Initial studies demonstrated a key role for mast cells in promoting
angiogenesis in squamous carcinoma and further work showed a
similar role in pancreatic tumors [15,16]. In a colorectal polyp
model, we demonstrated the importance of CD34 expression on
infiltrating mast cells, resulting in increased tumor angiogenesis in
polyp formation [17]. Eosinophils also infiltrate tumors, and may
mediate tumor rejection [18,19]. Since we have previously shown
a role for CD34 in both mast cell and eosinophil trafficking, we
speculated that CD34 ablation would affect immune cell
recruitment into the tumor microenvironment, with direct effects
on tumor growth.
In cancer studies, CD34 is often used as a marker of tumor
vasculature [20,21] and CD34
+ staining is used to characterize
vascular patterns within tumor tissues [22]. In the lone study
examining a functional role for CD34 in tumor cells, Cd34
2/2
mice exhibited reduced tumor growth, compared to wildtype
animals, following administration of 7,12-dimethylbenz(a)anthra-
cene (DMBA) and 12-O-tetradecanoylphorbol-13-acetate (TPA)
[23]. This growth difference resulted from a decreased capacity of
Cd34
2/2 hair follicle bulge stem cells (which normally express
CD34) to activate and switch to a proliferative state following TPA
exposure [23]. These findings demonstrated a cell-intrinsic role for
CD34 in follicle stem cell proliferation. However, the function of
CD34 in the tumor-extrinsic microenvironment has not been
thoroughly examined.
Despite the presence of CD34 on both the vasculature and
tumor-infiltrating immune cells, our study is the first to address a
role for CD34 in the tumor microenvironment and highlight a
tumor cell-extrinsic function for CD34 in tumor development. To
assess the function of CD34 on hematopoietic and non-
hematopoietic cells we implanted B16F1 melanoma cells into
wildtype and Cd34
2/2 mice, as well as bone marrow-reconstituted
chimeras. Our results show that at an early time-point, tumor
growth is decreased in Cd34
2/2 animals, in both primary tumors
(at day 14) and lung metastases (day 12), and that this is associated
with impaired vascular integrity. In contrast, at a later time-point
(day 19) tumor growth is increased in Cd34
2/2 animals, associated
with reduced intra-tumor mast cell numbers.
Results
Cd34
2/2 animals exhibit reduced tumor size at early
time-points
To determine the effect of CD34 ablation on tumor development
and metastasis, B16F1 cells were injected subcutaneously (s.c.)o r
intravenously (i.v.) into Cd34
2/2 and wildtype Cd34
+/+ C57Bl/6
mice. Fourteen days after s.c. injection, tumor size was significantly
smaller in Cd34
2/2 animals, compared to wildtype controls
(Figure 1A). Similarly, in the i.v. metastasis model, Cd34
2/2 mice
exhibited fewer metastatic lung nodules 12 days post-injection,
compared to wildtype controls (Figure 1B). Thus, CD34 is required
for efficient early tumor growth of both s.c. and i.v.-injected tumors.
As CD34 is expressed on the vascular endothelia, we character-
ized the expression pattern of CD34 in wildtype tumor tissue, and
also confirmed its absence on Cd34
2/2 tumor vessels by staining
tissue sections with antibodies recognizing CD34. Histological
analysesrevealedvascularCD34localization,aspreviouslyreported
[21], in an overlapping staining pattern with the common vascular
marker CD31 (Figure 1C). In tumors excised from Cd34
2/2 mice,
CD34 staining was absent and CD31 staining patterns were
unaffected (Figure 1C). Based on the previous findings of impaired
vessel integrity in Cd34
2/2 mice [11], we also assayed vascular
integrity in tumor tissues by injecting mice with fluorescent
carbocyanine dye prior to sacrifice. Interestingly, carbocyanine
fluorescencewasmoreintenseinCd34
2/2tumortissues(Figure1C),
as quantified and discussed in depth below. These findings
demonstrate increased vascular dye leakage in Cd34
2/2 mice,
suggestingaroleforCD34inmaintainingtumorvesselintegrityand
demonstrate that CD34 is required for optimal early tumor growth.
Reduced tumor size at early time-points is due to loss of
CD34 expression on non-hematopoietic cells
Several different cell types express CD34, including vascular
endothelia and hematopoietic cells (predominantly mast cells and
eosinophils). To assess whether loss of CD34 on hematopoietic or
non-hematopoietic cells was responsible for the altered tumor
growth observed at day 14, we generated bone marrow-
reconstituted chimeras. Wildtype and Cd34
2/2 animals were
irradiated and reconstituted with bone marrow from wildtype
Ly5.1 congenic animals. These chimeras retain wildtype CD34
expression on hematopoietic lineages, but lack CD34 on non-
hematopoietic tissues. Again, Cd34
2/2 animals reconstituted with
wildtype bone marrow exhibited reduced tumor size 14 days post-
s.c. injection, compared to Cd34
+/+ animals reconstituted with
wildtype bone marrow, as assessed by tumor volume measure-
ments (Figure 2A,B).
To assess the importance of CD34 expression on hematopoietic
lineages at the day 14-end-point, we generated reciprocally
transplanted chimeras: wildtype Ly5.1 mice were reconstituted
with either Cd34
+/+ or Cd34
2/2 bone marrow. Strikingly, in these
chimeras, there was no significant difference in tumor size 14 days
post-injection (Figure 2C). These findings demonstrate that CD34
ablation in non-hematopoietic cells results in reduced early s.c.
tumor growth, while CD34 ablation in hematopoietic cells has no
effect at the day 14 time-point.
Reduced tumor size in Cd34
2/2 mice is associated with
increased vascular permeability and altered vessel
structure
Since the observed difference in s.c. tumor growth results from
loss of CD34 in non-hematopoietic cells and we have previously
shown increased vascular leakage in an inflammatory model [11],
we focused our studies on quantifying vascular integrity in tumors.
Mice were injected with fluorescent carbocyanine 5 minutes
before sacrifice and fluorescence intensity was quantified in tumor
sections based on proximity to tumor vasculature. Carbocyanine
fluorescence intensity was consistently increased proximal to the
vasculature in Cd34
2/2 tumors, compared to Cd34
+/+ tumors, and
steadily decreased with increasing distance away from the vessel
(Figure 3A,B).
A more detailed quantification of stained sections revealed no
difference in vessel density, as assessed by the average distance of
each pixel from the nearest CD31
+ pixel (Figure 3C). Analysis of
carbocyanine/CD31 co-localization did reveal a slightly higher
proportion of perfused vessels in Cd34
2/2 tumor tissues,
compared to Cd34
+/+, suggestive of a slight increase in the
proportion of functional vessels (Figure 3D). However, further
analysis demonstrated no differences in overall tumor vascularity
CD34 and Melanoma Growth
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impaired in Cd34
2/2 mice, CD34 ablation has no observable
effect on general tumor angiogenesis.
In separate experiments, tumor vasculature was imaged using
computed tomography (CT). CT images reveal an organized
vascular network in tumors from Cd34
+/+ mice, with large vessels
of uniform diameter at the tumor periphery and an intricately
branched microvascular network throughout the tumor interior
(Figure 3E). In contrast, tumors from Cd34
2/2 mice consistently
exhibited less organized vascular networks, with variability in the
shape and size of large vessels, which appeared shorter and more
bulbous (Figure 3F). In summary, we observed increased vascular
leakage and altered vessel structure in tumors from Cd34
2/2 mice,
suggesting a role for CD34 in the maintenance of tumor vessel
integrity, a limiting factor in tumor growth.
Cd34
2/2 mice exhibit increased tumor cell extravasation
in a metastasis model
Impaired vascular integrity is likely to have several important
consequences on tumor cell metastasis including: 1) impaired
expansion of existing metastases, due to reduced tumor growth (as
observed in primary tumors) and 2) an enhanced ability of tumor
cells to initially colonize new sites, due to decreased endothelial
junction integrity. To address the latter effect, we revisited our
initial metastasis studies to determine the effect of CD34 ablation
on initial tumor cell extravasation into the lung. Mice were
Figure 1. Melanoma growth is reduced in Cd34
2/2 animals at day 14, with CD34 expression on vasculature. A, Average tumor mass 14
days after subcutaneous injection of 5610
5 B16F1-OVA cells. (Pooled from three experiments, Cd34
+/+ n=12; Cd34
2/2 n=15). B, Average number of
lung metastases 12 days after intravenous injection of 3610
5 B16F1-OVA cells. (Cd34
+/+ n=5,Cd34
2/2 n=6, *represents p,0.05; Error bars=SEM). C,
Representative photomicrographs from s.c.-injected tumor sections stained for CD34 and CD31 or carbocyanine fluorescence, as indicated (CD31-red,
CD34-blue, carbocyanine-green).
doi:10.1371/journal.pone.0018160.g001
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dextran, to visualize intact vasculature, and lung tissues were
extracted after four hours. Fluorescent B16F1 cells were visible
within lung sections (Figure 4A - green), with no difference in total
tumor cell numbers between Cd34
+/+ and Cd34
2/2 lungs (data not
shown). Fluorescent dextran localization highlighted the lung
microvasculature (Figure 4A - red) and increased dextran leakage
was seen in Cd34
2/2 lungs, compared to Cd34
+/+ lungs. Merged
images (Figure 4A) were used to quantify the proportion of total
tumor cells that migrated into the lung parenchyma, revealing
increased tumor cell extravasation in Cd34
2/2 lungs, compared to
Cd34
+/+ controls (Figure 4B). These findings suggest that the
impaired vessel integrity observed in Cd34
2/2 tumor vasculature
also occurs in the lung microvasculature, resulting in an increased
initial cell extravasation in Cd34
2/2 lungs. However, despite
enhanced initial colonization in the lung, the later requirement for
CD34 to maintain vascular integrity and promote tumor growth is
dominant and CD34 ablation results in fewer detectable
metastases at the day 12 time-point (Figure 1B).
Cd34
2/2 animals exhibit a paradoxical increased tumor
growth at later time-points, as a result of CD34 loss on
hematopoietic cells
As tumor size was significantly reduced 14 days post-injection, we
hypothesized that this difference would increase at later time-points.
To address this hypothesis, tumors in Cd34
2/2 animals were
weighed 19 days post-injection. Between day 14 and day 19, tumors
masses increased dramatically from ,0.4 grams to .1.0 gram in
wildtype mice. Surprisingly, tumor size in Cd34
2/2 animals
approached or even surpassed tumor size in Cd34
+/+ control
animals, at the day 19 end-point (Figure 5A).
To determine the relative importance of CD34 expression on
hematopoietic versus non-hematopoietic cells at this time-point,
tumor cells were, again, implanted into bone marrow chimeric
animals. Ly5.1 mice reconstituted with Cd34
2/2 bone marrow
exhibited increased tumor size on day 19, compared to mice
reconstituted with Cd34
+/+ bone marrow (Figure 5B). These
findings suggest that, at late stages, CD34 expression on
hematopoietic cells limits tumor growth and that CD34 ablation
in hematopoietic cells results in increased tumor growth. As
hematopoietic CD34 is predominantly expressed on mast cells and
eosinophils, we further examined the roles of these cells in
regulating tumor growth.
Cd34
2/2 intra-tumoral mast cell infiltration is impaired
Mast cells play many roles in tumor development, with
functions in both tumor promotion and suppression [14]. Further,
the localization of mast cell populations within and around
developing tumors can have opposing effects on tumor growth
[24]. Since we previously showed that CD34 is required for
efficient mast cell homing and migration [6,12], we quantified the
number of mast cells in tumors from Cd34
+/+ and Cd34
2/2 mice.
Toluidine blue staining revealed mast cell accumulation around
the periphery of developing tumors, with the majority of mast cells
Figure 2. Reduced subcutaneous tumor size at day 14 correlates with loss of CD34 on non-hematopoietic cells. A, Average tumor mass
and B, volume at day 14 in Cd34
+/+ or Cd34
2/2 animals reconstituted with wildtype Ly5.1 bone marrow. (Pooled from two experiments, Cd34
+/+
n=13, Cd34
2/2 n=14). C, Average tumor mass at day 14, in reciprocal reconstitutions of wildtype Ly5.1 animals with Cd34
+/+ or Cd34
2/2 bone
marrow (n=9, *represents p,0.05; Error bars=SEM).
doi:10.1371/journal.pone.0018160.g002
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tumoral; Figure 6A) and a small number of mast cells penetrating
into tumor tissue (intra-tumoral; Figure 6B).
At the early (day 14) time-point, peri-tumoral and intra-tumoral
mast cell numbers were slightly reduced (p=0.07) in tumors from
Cd34
2/2 animals, compared to Cd34
+/+ controls (Figure 6C), with
the reduction in intra-tumoral mast cell numbers being significant
at the day 19 time-point (Figure 6D). In tumors from chimeric
animals, chimeras lacking CD34 on non-hematopoietic tissues
exhibited no difference in mast cell infiltration at the day 14 time-
point (Figure 6E). Conversely, at day 19, chimeras lacking
hematopoietic CD34 expression exhibited reduced intra-tumoral
mast cell numbers, compared to chimeras reconstituted with
wildtype bone marrow (Figure 6F). These findings reveal reduced
mast cell tumor infiltration at all time-points when CD34 is
ablated on hematopoietic lineages, most significantly at late stages,
resulting in decreased numbers of intra-tumoral mast cells.
Discussion
CD34 expression in the tumor microenvironment has been
extensively reported in human and mouse cancers. Notably, CD34
expression is generally absent in melanocytic tumor samples [22]
and in the current studies, we found no significant CD34 staining
on murine melanoma cells (Figure 1C). Thus any role for CD34 in
tumor progression is likely restricted to a tumor cell-extrinsic
Figure 3. Increased carbocyanine leakage and altered vessel morphology in subcutaneously-injected tumors from Cd34
2/2 animals.
Carbocyanine fluorescence intensity quantified A, proximal to CD31
+ vessels (at distance 0 mm) and B, with increasing distance from the nearest
vessel (CD31
+), in day 14 tumors. C, Average distance of each pixel within the tumor tissue from the nearest CD31
+ staining pixel. D, Perfused vessels
(%), corresponding to the percentage of CD31
+ pixels colocalized with carbocyanine staining. For carbocyanine data, one outlier per genotype was
removed prior to analysis. (n=5 for carbocyanine, n=6 for average distance, *represents p,0.05; **represents p,0.01; Error bars=SEM).
Representative CT images of tumors excised 14 days post-injection and perfused with Microfil contrast reagent from E, Cd34
+/+ and F, Cd34
2/2 mice.
Scale bars, 2 mm (n=3).
doi:10.1371/journal.pone.0018160.g003
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broad range of tumor types, CD34 is expressed on tumor
vasculature and on spindle cells in a variety of skin lesions [22].
Within these lesions, CD34 expression has been used diagnosti-
cally [22] and has been proposed as a prognostic indicator, as
CD34 staining correlates with the extent of tumor angiogenesis
[25]. In mouse models, CD34 staining has also been used to
quantify microvessel density [20,21]. To our knowledge, however,
the functional significance of the CD34 molecule itself, on the
tumor vasculature, has not been addressed.
We previously demonstrated a role for endothelia-expressed
CD34 in the maintenance of vessel integrity in a murine model of
rheumatoid arthritis [11]. Cd34
2/2 mice exhibited increased
vascular leakage in distal joints in response to autoimmune serum
(leading to worsened disease outcomes) and following TNFa
treatment [11]. The loss of the CD34-related molecule, podoca-
lyxin, also delays aortic lumen formation during early embryo-
genesis [10]. Further, podocalyxin and CD34 both localize to the
site of vascular lumen initiation in Lewis Lung carcinoma tumor-
associated vasculature [10]. Thus, although the function of this
family of proteins on tumor vasculature has never been directly
addressed, there is a precedent to suggest a role for these molecules
in both vessel formation and the maintenance of vascular integrity.
In the current study, we observed biphasic functional roles for
CD34 in the tumor microenvironment during tumor progression
(Figure 7). At an early time-point (day 14), loss of CD34 on non-
hematopoietic cells affected tumor vasculature resulting in
decreased tumor size, increased vascular leakage and altered
vessel morphology. Reduced numbers of lung metastases were also
observed in Cd34
2/2 mice at day 12, despite increased initial
tumor cell extravasation into the lung 4 hours after injection. All
these phenotypes support a role for CD34 on vascular endothelial
cells, consistent with the findings of a role for the CD34 family of
proteins in maintaining vascular integrity in both inflammatory
disease and embryonic development [10,11].
Although we detect impaired vessel integrity at an early time-
point, we observed no significant differences in vessel density
(Figure 3C) or vascularization between Cd34
+/+ and Cd34
2/2
tumors, suggesting that impairment may occur early in tumor
growth or may be quite subtle. In support of the second
hypothesis, we found increased tissue carbocyanine leakage,
altered vessel morphology and increased tumor cell extravasation
in the lungs of Cd34
2/2 mice, compared to wildtype animals.
These findings support the conclusion that CD34 is involved in the
maintenance or establishment of vessel integrity within the tumor
microenvironment. In light of these findings, extra care should be
Figure 4. Increased tumor cell extravasation in Cd34
2/2 animals. A, CMFDA-labeled B16F1 cells (green) were coinjected i.v. with fluorescent
dextran (red) and lungs were removed after 4 hours, fixed, sectioned and imaged. Representative sections are shown. Tumor cells were quantified as
extravasated (green – solid arrows), or within the microvasculature (yellow – hollow arrows). Scale bar, 50 mm, inset=26zoom. B, Proportion (%) of
tumor cells extravasated per section (n=5 lungs per genotype, .5 sections per lung, *represents p,0.05; Error bars=SEM).
doi:10.1371/journal.pone.0018160.g004
Figure 5. Tumor size in Cd34
2/2 surpasses Cd34
+/+ by day 19, due to hematopoietic loss of CD34. A, Average s.c.-injected tumor masses
19 days post-injection in Cd34
+/+ and Cd34
2/2 animals. (Pooled from three experiments, Cd34
+/+ n=15, Cd34
2/2 n=16). B, Average tumor mass at
day 19 in wildtype Ly5.1 animals reconstituted with either Cd34
+/+ or Cd34
2/2 bone marrow. (Pooled from two experiments, Cd34
+/+ into Ly5.1 n=11,
Cd34
2/2 into Ly5.1 n=13). (*represents p,0.05; Error bars=SEM).
doi:10.1371/journal.pone.0018160.g005
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tumor vasculature. Based on our findings, we predict that if CD34
expression is lost or reduced on tumor vasculature, there would be
functional effects on vascular integrity and tumor growth. As such,
multiple vascular markers should be used to ensure all tumor
vasculature is recognized and further studies should be performed
to determine whether CD34
2 vasculature is present in different
tumor subsets.
It should be noted that the reduced tumor mass at day 14 in
reconstituted Cd34
2/2 animals (Figure 2A/B) was less severe than
the reduction in non-irradiated, non-reconstituted Cd34
2/2
animals (Figure 1A). This suggests that while CD34 ablation,
specifically on non-hematopoietic cells, results in impaired tumor
growth, CD34 expression on hematopoietic cells may also play a
lesser role. In non-reconstituted Cd34
2/2 mice we observed
reduced mast cell numbers, which was not observed in tumors
from Cd34
2/2 mice reconstituted with Cd34
+/+ bone marrow
(Figure 6C,E). Mast cells are thought to promote tumor growth by
inducing angiogenesis and remodeling the tumor microenviron-
ment in certain situations [14]. In fact, mast cell-deficient W/W
v
mice exhibit decreased early tumor growth in a B16 melanoma
model [26]. We propose that endothelial-expressed CD34 is most
important for early tumor growth by maintaining vascular integrity,
but the reduction in mast cell accumulation in Cd34
2/2 mice may
also alter angiogenesis and play a minor role at the early time-point
(day 14).
At the latertime-point(day19), we found that tumorsize isincreased
in Cd34
2/2 mice, following CD34 ablation in hematopoietic cells
Figure 6. Mast cell tumor infiltration is reduced in Cd34
2/2 mice. Toluidine blue staining of A, peri-tumoral mast cells in tissues surrounding
tumors and B, intra-tumoral mast cells within tumor tissues. (arrows, mast cells; dotted line, tumor boundary). Mast cell counts in s.c.-injected tumors
from Cd34
+/+ and Cd34
2/2 animals at C, day 14 (pooled from three experiments, Cd34
+/+ n=13, Cd34
2/2 n=16) and D, day 19 (pooled from three
experiments, n=13). Counts in tumors from E, Cd34
+/+ or Cd34
2/2 animals reconstituted with wildtype Ly5.1 marrow at day 14 (pooled from three
experiments, Ly5.1 into Cd34
+/+ n=13, Ly5.1 into Cd34
2/2 n=14) and F, in wildtype Ly5.1 animals reconstituted with either Cd34
+/+ or Cd34
2/2 bone
marrow at day 19 (pooled from three experiments, Cd34
+/+ into Ly5.1 n=11, Cd34
2/2 into Ly5.1 n=13). (*represents p,0.05; Error bars=SEM).
doi:10.1371/journal.pone.0018160.g006
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predominantly on mast cells and eosinophils. Intra-tumoral mast cell
infiltration was reduced at all time-points following Cd34 ablation in
hematopoietic cells and, while mast cells have been suggested to play
pro-tumorigenic roles, studies have also indicated a role for mast cells in
anti-tumoral immunity [24]. In addition to mast cells, eosinophils play
a role in tumor rejection in B16 tumors [18,19,27]. Our previous
studies have demonstrated a key role for CD34 in optimal eosinophil
migration in vivo and in vitro [6,7] and we speculate that increased tumor
growth at the late time-point in Cd34
2/2 mice may also be due in part
to impaired eosinophil migration, resulting in reduced tumor
clearance. Thus we propose that the impaired intra-tumoral mast cell
and eosinophil infiltration, in Cd34
2/2 mice, results in decreased
tumor clearance and increased tumor growth at the late time-point.
In conclusion, our study demonstrates that CD34 promotes
tumor growth at an early time-point (day 14), by playing a key role
on vasculature, maintaining appropriate vessel integrity. In
Cd34
2/2 animals at all time-points, intra-tumoral mast cell
numbers are reduced, and at a later time-point (day 19) tumor
growth surpasses Cd34
+/+ controls. The difference at the later
time-point can be attributed to CD34 loss on hematopoietic cells
and likely reflects a reduced capacity of Cd34
2/2 mast cells and
eosinophils to dampen tumor growth and induce immune tumor
rejection. This study presents novel insights into CD34 function on
vasculature and expands our understanding of a role for CD34 in
hematopoietic cell migration during tumor development.
Materials and Methods
Ethics Statement
All experiments and procedures were approved by the
Committee on Animal Care (Protocol #A07-0258 and #A07-
0399) at the University of British Columbia, in accordance with
the requirements of the Canadian Council on Animal Care
(CCAC).
Mice
Cd34
2/2 (provided by Dr. T. W. Mak. [28]) and C57Bl/6 mice
were used for all experiments. Six to ten week old gender-matched
mice were maintained in specific pathogen-free conditions at The
Biomedical Research Centre.
Bone marrow reconstitutions
Bone marrow chimeras were generated using the Ly5.1/5.2
reconstitution system,aspreviouslydescribed [6]. Bone marrowwas
Figure 7. CD34 function in the tumor microenvironment. Model schematic of CD34 function in the tumor microenvironment, highlighting
effects on vascular integrity, associated with decreased tumor growth at an early time-point (day 14) and immune cell accumulation, associated with
increased tumor growth at a later time-point (day 19) in Cd34
2/2 mice.
doi:10.1371/journal.pone.0018160.g007
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+/+ (Ly 5.2) and Cd34
2/2 (Ly 5.2) or
Ly5.1 mice and transplanted into recipient Ly5.1 or Cd34
+/+ and
Cd34
2/2 mice respectively, as specified in the text. Cells (,10
6)
wereintravenously injected into lethally-irradiated (11 Gy)recipient
animals. After ten weeks, reconstitution levels were evaluated by
assessing Ly 5.2 and Ly 5.1 expression in blood and mice were
considered reconstituted when hematopoietic cells were .80%
donor-derived.
Subcutaneous and lung metastasis tumor induction
B16F1-OVA cells (provided by Dr. C. Parrish [18]) were
maintained in RPMI supplemented with 10% FBS, penicillin,
streptomycin and L-glutamine. For subcutaneous models,
5610
5 cells were injected into the fore flank and tumors grown
for 14 to 19 days, as indicated in the text. Tumor size was
quantified by measuring final tumor mass and tumor volume
using manual calipers (calculated as (L6W
2)/2). Excised solid
tumors for H&E and toluidine blue histology were fixed
overnight in 10% buffered formalin and paraffin-embedded.
For immunohistochemistry studies, tumors were excised and
frozen at 220 C, then embedded in OCT (Tissue-TEK). Lung
metastases were induced by intravenous injection of 3610
5
B16F1-OVA cells and mice were sacrificed after 12 days to
quantify lung tumor numbers.
Histology
To assess tumor mast cell numbers, toluidine blue staining was
performed on fixed tumor sections. Mast cells were counted in
tissue bordering tumors (peri-tumoral) and within tumor tissue
(intra-tumoral) and normalized to tumor circumference and tumor
area respectively. Slides were analyzed on a Zeiss Axioplan2
microscope (Toronto, ON) and images were captured using a
Qimaging Retiga EX CCD camera (Minneapolis, MN) and
Openlab 4.0.4 software.
Immunohistochemistry was performed as previously described
[29,30]. Five minutes prior to euthanization, mice were
intravenously administered 0.6 mg/mL fluorescent carboycya-
nine (Molecular Probes), dissolved in 75% (v/v) DMSO: 25%
sterile water. Tissue sections were prepared 2–3 mm from the
tumor edge, dried and imaged for fluorescence, then fixed in 50%
(v/v) acetone/methanol. Tissues were stained using antibodies
recognizing CD31 (MEC 13.3, BD PharMingen) and CD34
antibody (RAM34, BD PharMingen). Tissues were imaged using
a robotic fluorescence microscope (Zeiss Imager Z1), a cooled,
monochrome CCD camera (Retiga 4000R, Qimaging), a
motorized slide loader and x-y stage (Ludl Electronic Products)
and customized NIH-ImageJ software. Images were inverted,
overlaid and cropped, with staining artifacts removed. Carbo-
cyanine intensity was assessed by sorting pixels based on relative
distance from CD31-positive vessels, reported in 1.5 mm
increments, after subtracting background-staining intensity.
Vessel density was assessed by measuring the relative distance
of each pixel from the nearest CD31
+ pixel and vessel perfusion
was assessed by colocalization of carbocyanine fluorescence with
CD31 staining.
Computed tomography (CT) imaging
Mice were anaesthetized with ketamine/xylazine, injected
subcutaneously with heparin (500 U; Sigma, St. Louis, MO) and
perfused with warmed PBS followed by a solidifying silicone
rubber contrast agent (Microfil MV-122; Flow Tech, Carver, MA).
Mice were kept on ice for two hours for curing, after which tumors
were excised and stored in 10% EDTA for two weeks for
decalcification. Tumors were scanned on a micro-CT imaging
system (vivaCT 40, Scanco Medical, Bassersdorf, Switzerland) at
45 kVp, 177 mA with a 10.5 mm voxel size. All images were
prepared at the same threshold values
Tumor extravasation studies
2.5610
5 B16F1 cells (American Type Culture Collections),
labeled with CellTracker Green dye (CMFDA; Molecular Probes,
Invitrogen), were coinjected intravenously with 5 mg/kg Alexa-
Fluor647-dextran (Molecular Probes, Invitrogen), as previously
described [31]. After four hours, lungs were removed, fixed in
paraformaldehyde, embedded in OCT, sectioned and imaged
using the UPlan Fluorite 206/0.7 NA objective of an Olympus
FV1000 confocal microscope. Five or more sections were analyzed
for each lung sample.
Statistical analysis
P values were calculated using unpaired two-sample student t
tests.
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